Chemotherapeutics in the treatment of multiple sclerosis

Therapeutic Advances in Neurological Disorders

Volumn 3, Issue 5, 2010, Pages 277-291

  Kieseier, Bernd C ^a   Jeffery, Douglas R ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

chemotherapeutic; glatiramer acetate; immunomodulatory; immunosuppressive; interferon beta; multiple sclerosis; risk benefit; toxicity

Indexed keywords

ALEMTUZUMAB; ALPHA4 INTEGRIN; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CELL ADHESION MOLECULE; CLADRIBINE; CYCLOPHOSPHAMIDE; GLATIRAMER; INTERFERON BETA SERINE; METHOTREXATE; MITOXANTRONE; NATALIZUMAB; RITUXIMAB;

ACUTE GLOMERULONEPHRITIS; ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; AMENORRHEA; ANEMIA; BLADDER CANCER; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOLOGIC MALIGNANCY; HEMORRHAGIC CYSTITIS; HEPATITIS B; HERPES ZOSTER; HUMAN; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; INFERTILITY; INJECTION SITE REACTION; INTESTINE PERFORATION; LEIOMYOMA; LEUKEMIA; LIVER FIBROSIS; LIVER TOXICITY; LUNG TOXICITY; LYMPHOCYTE COUNT; MENSTRUATION DISORDER; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; NAUSEA; NEOPLASM; NEPHROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RASH; RELAPSE; REVIEW; RIGOR; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SECOND CANCER; SIDE EFFECT; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; TUMOR LYSIS SYNDROME; ULCERATIVE COLITIS; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 77957339494     PISSN: 17562856     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756285610379885     Document Type: Review

References (101)

1. Arnason, B.G., Dayal, A., Qu, Z.X., Jensen, M.A., Genç, K. and Reder, A.T. ( 1996) Mechanisms of action of interferon-beta in multiple sclerosis. Springer Sem Immunopathol 18: 125-148.
2. Arnold, D.L., Campagnolo, D., Panitch, H., Bar-Or, A., Dunn, J., Freedman, M.S. et al. (2008) Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. J Neurol 255: 1473-1478.
3. Beutler, E., Sipe, J.C., Romine, J.S., Koziol, J.A., McMillan, R. and Zyroff, J. ( 1996) The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A 93: 1716-1720.
4. CAMMS223 Trial Investigators, Coles, A.J., Compston, D.A., Selmaj, K.W., Lake, S.L., Moran, S., Margolin, D.H. et al. (2008 ) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359: 1786-1801.
5. Campath (alemtuzumab) US prescribing information. Last accessed 11 November 2009 berlex.bayerhealthcare.com/html/products/pi/Campath_PI.pdf.
6. Carrá, A., Onaha, P., Luetic, G., Burgos, M., Crespo, E., Deri, N. et al. (2008) Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. Eur J Neurol 15: 386-393.
7. Casetta, I., Iuliano, G. and Filippini, G. ( 2007) Azathioprine for multiple sclerosis. Cochrane Database Syst Rev CD003982, DOI: 10.1002/ 14651858.CD003982.pub2.
8. Chan, A., Weilbach, F.X., Toyka, K.V. and Gold, R. ( 2005) Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 139: 152-158.
9. Clifford, D.B., de Luca, A., Simpson, D.M., Arendt, G., Giovannoni, G. and Nath, A. (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9: 438-446.
10. Cohen, J.A., Imrey, P.B., Calabresi, P.A., Edwards, K.R., Eickenhorst, T., Felton, W.L. et al. (2009) Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology 72: 535-541.
11. Coles, A.J., Wing, M.G., Molyneux, P., Paolillo, A., Davie, C.M., Hale, G. et al. (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46: 296-304.
12. Coles, A.J., Cox, A., Le Page, E., Jones, J., Trip, S.A., Deans, J. et al. (2006) The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253: 98-108.
13. Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, O. et al. (2001 a) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357: 1576-1582.
14. Comi, G., Filippi, M. and Wolinsky, J.S. and the European / Canadian Glatiramer Acetate Study Group. ( 2001b) European / Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 49: 290-297.
15. Comi, G., Cook, S., Giovannoni, G., Rammohan, K., Rieckmann, P., Sorensen, P.S. et al. (2009) Reductions in MRI activity in relapsing-remitting multiple sclerosis achieved with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. Mult Scler 15(Suppl 2): S136, Abstract P 469.
16. Confavreux, C., Saddier, P., Grimaud, J., Moreau, T., Adeleine, P. and Aimard, G. ( 1996) Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 46: 1607-1612.
17. Cook, S., Vermersch, P., Comi, G., Giovannoni, G., Rammohan, K., Rieckmann, P. et al. (2009) Safety and tolerability of cladribine tablets in relapsing-remitting multiple sclerosis during the 96-week, phase III, double-blind, placebo-controlled CLARITY study. Mult Scler 15(Suppl 2): S21, Abstract 88.
18. Cotte, S., von Ahsen, N., Kruse, N., Huber, B., Winkelmann, A., Zettl, U.K. et al. (2009) ABCtransporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain 132: 2517-2530.
19. Cyclophosphamide US prescribing information. Last accessed 11 November 2009, http://www.mims.com/Page.aspx?menuid=mng&CTRY=US&Name=Cyclophosphamide+Tablet.
20. Dörr, J., Bitsch, A., Schmailzl, K.J., Chan, A., von Ahsen, N., Hummel, M. et al. (2009) Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurology 73: 991-993.
21. Edan, G., Miller, D., Clanet, M., Confavreux, C., Lyon-Caen, O., Lubetzki, C. et al. (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62: 112-118.
22. Ellis, R. and Boggild, M. (2009) Therapy-related acute leukaemia with mitoxantrone: what is the risk and can we minimise it? Mult Scler 15: 505-508.
23. Etemadifar, M., Janghorbani, M. and Shaygannejad, V. ( 2007) Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. J Neurol 254: 1723-1728.
24. Fernandez, O. ( 2007) Combination therapy in multiple sclerosis. J Neurol Sci 259: 95-103.
25. Filippi, M., Rovaris, M., Iannucci, G., Mennea, S., Sormani, M.P. and Comi, G. ( 2000a) Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 55: 1714-1718.
26. Filippi, M., Rovaris, M., Rice, G.P., Sormani, M.P., Iannucci, G., Giacomotti, L. et al. (2000 b) The effect of cladribine on T (1) ‘black hole’ changes in progressive MS. J Neurol Sci 176: 42-44.
27. Fleischmann, R.M. ( 2009) Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 60: 3225-3228.
28. Ghalie, R.G., Mauch, E., Edan, G., Hartung, H.P., Gonsette, R.E., Eisenmann, S. et al. (2002) A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 8: 441-445.
29. Gilden, D.H. ( 2005) Infectious causes of multiple sclerosis. Lancet Neurol 4: 195-202.
30. Giovannoni, G., Comi, G., Cook, S., Rammohan, K., Rieckmann, P., Sorensen, P.S. et al. (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 362: 416-426.
31. Gladstone, D.E., Zamkoff, K.W., Krupp, L., Peyster, R., Sibony, P., Christodoulou, C. et al. (2006) High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol 63: 1388-1393.
32. Gold, R. ( 2008) Combination therapies in multiple sclerosis. J Neurol 255(Suppl 1): 51-60.
33. Gonsette, R.E. ( 2008) Oxidative stress and excitotoxicity: a therapeutic issue in multiple sclerosis. Mult Scler 14: 22-34.
34. Goodkin, D.E., Plencner, S., Palmer-Saxerud, J., Teetzen, M. and Hertsgaard, D. ( 1987) Cyclophosphamide in chronic progressive multiple sclerosis: maintenance vs nonmaintenance therapy. Arch Neurol 44: 823-827.
35. Gray, O., McDonnell, G.V. and Forbes, R.B. ( 2004) Methotrexate for multiple sclerosis. Cochrane Database Syst Rev 2: CD003208.
36. Gray, O.M., McDonnell, G.V. and Forbes, R.B. ( 2006) A systematic review of oral methotrexate for multiple sclerosis. Mult Scler 12: 507-510.
37. Hartung, H.P., Gonsette, R., König, N., Kwiecinski, H., Guseo, A., Morrissey, S.P. et al. (2002) Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360: 2018-2025.
38. Hauser, S., Dawson, D., Lehrich, J., Beal, M.F., Kevy, S.V., Propper, R.D. et al. (1983) Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 308: 173-180.
39. Hauser, S.L., Waubant, E., Arnold, D.L., Vollmer, T., Antel, J., Fox, R.J. et al. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358: 676-688.
40. Hawker, K., O'Connor, P., Freedman, M.S., Calabresi, P.A., Antel, J., Simon, J. et al. (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66: 460-471.
41. Hutchinson, M., Kappos, L., Calabresi, P.A., Confavreux, C., Giovannoni, G., Galetta, S.L. et al. (2009) The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 256: 405-415.
42. Jacobs, L.D., Cookfair, D.L., Rudick, R.A., Herndon, R.M., Richert, J.R., Salazar, A.M. et al. (1996) The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39: 285-294.
43. Jeffery, D.R., Chepuri, N., Durden, D. and Burdette, J. ( 2005) A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Mult Scler 11: 296-301.
44. Johnson, K.P., Brooks, B.R., Cohen, J.A., Ford, C.C., Goldstein, J., Lisak, R.P. et al. (1995) The Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 45: 1268-1276.
45. Kappos, L., Polman, C.H., Freedman, M.S., Edan, G., Hartung, H.P., Miller, D.H. et al. (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67: 1242-1249.
46. Kappos, L., Freedman, M.S., Polman, C.H., Edan, G., Hartung, H.P., Miller, D.H. et al. (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370: 389-397.
47. Khan, O.A., Zvartau-Hind, M., Caon, C., Din, M.U., Cochran, M., Lisak, D. et al. (2001) Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult Scler 7: 185-188.
48. Kieseier, B.C., Putzki, N., Bates, D., Hutchinson, M., Pace, A. and Hyde, R. ( 2009) Improvement in quality-of-life outcomes with natalizumab in multiple sclerosis patients with highly active disease. Neurology 72(Suppl 3): A238.
49. Kinkel, R.P., Kollman, C., O'Connor, P., Murray, T.J., Simon, J., Arnold, D. et al. (2006) IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66: 678-684.
50. Kopadze, T., Dehmel, T., Hartung, H.P., Stüve, O. and Kieseier, B.C. ( 2006) Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis. Arch Neurol 63: 1572-1578.
51. Krapf, H., Morrissey, S.P., Zenker, O., Zwingers, T., Gonsette, R. and Hartung, H.P. for the MIMS Study Group. (2005) Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology 65: 690-695.
52. Le Page, E., Leray, E., Taurin, G., Coustans, M., Chaperon, J., Morrissey, S.P. et al. (2008) Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 79: 52-56.
53. Le Page, E. and Edan, G. ( 2009) Long-term experience with induction treatment regimens in multiple sclerosis. J Neurol Sci 277(Suppl 1): S46-S49.
54. Leustatin (cladribine) US prescribing information. Last accessed 11 November 2009, http://www.orthobiotech.com/orthobiotech/shared/OBI/PI/Leustatin_PI.pdf.
55. Lhermitte, F., Marteau, R. and Roullet, E. ( 1984) Not so benign long-term immunosuppression in multiple sclerosis. Lancet 1: 276-277.
56. Likosky, W.H., Fireman, B., Elmore, R., Eno, G., Gale, K., Goode, G.B. et al. (1991) Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry 54: 1055-1060.
57. Linker, R. and Kieseier, B.C. ( 2008) Innovative therapy with monoclonal antibodies in multiple sclerosis. Ther Adv Neurol Disord 1: 33-42.
58. Markowitz, C.E. ( 2007) Interferon-beta: mechanism of action and dosing issues. Neurology 68(24 Suppl 4): S8-S11.
59. Marriott, J.J., Miyasaki, J.M., Gronseth, G. and O'Connor, P.W. ( 2010) Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis. Neurology 74: 1463-1470.
60. Martinelli, V. ( 2009) Leukemia risk with Mitoxantrone for multiple sclerosis. American Academy of Neurology 61st Annual Meeting, Seattle, WA, 25 April-2 May 2009. Abstract LB3.001.
61. Methotrexate US prescribing information. Last accessed 11 November 2009, http://www.mims.com/Page.aspx?menuid=mng&CTRY=US&Name=Methotrexate+Injection%2C+Solution.
62. Millefiorini, E., Gasperini, C., Pozzilli, C., D'Andrea, F., Bastianello, S., Trojano, M. et al. (1997) Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 244: 153-159.
63. Morrissey, S.P., Le Page, E. and Edan, G. ( 2005) Mitoxantrone in the treatment of multiple sclerosis. Int Mult Scler J 12: 74-87.
64. Neuhaus, O., Wiendl, H., Kieseier, B.C., Archelos, J.J., Hemmer, B., Stüve, O. et al. (2005) Multiple sclerosis: mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol 168: 128-137.
65. Neuhaus, O., Kieseier, B.C. and Hartung, H.P. ( 2006) Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacol Ther 109: 198-209.
66. Noseworthy, J.H., Lucchinetti, C., Rodriguez, M. and Weinshenker, B.G. ( 2000) Multiple sclerosis. N Engl J Med 343: 938-952.
67. Novantrone (mitoxantrone) US prescribing information. Last accessed 9 November 2009, http://www.novantrone.com/assets/pdf/novantrone_prescribing_info.pdf.
68. Paolillo, A., Coles, A.J., Molyneux, P.D., Gawne-Cain, M., MacManus, D., Barker, G.J. et al. (1999) Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 53: 751-757.
69. Platten, M. and Steinman, L. ( 2005) Multiple sclerosis: trapped in deadly glue. Nat Med 11: 252-253.
70. Polman, C.H., O'Connor, P.W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D.H. et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910.
71. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group ( 1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing / remitting multiple sclerosis. Lancet 352: 1498-1504.
72. Racke, M.K. ( 2008) The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies. Curr Opin Neurol 21(Suppl 1): S9-S18.
73. Racke, M.K., Lovett-Racke, A.E. and Karandikar, N.J. (2010) The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology 74(Suppl 1): S25-S30.
74. Rejdak, K., Petzold, A., Stelmasiak, Z. and Giovannoni, G. ( 2008) Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. Mult Scler 14: 59-66.
75. Rice, G.P., Filippi, M. and Comi, G. ( 2000) Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 54: 1145-1155.
76. Rieckmann, P., Comi, G., Cook, S., Giovannoni, G., Rammohan, K., Sorensen, P.S. et al. (2009) Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96-week, phase III, double-blind, placebo-controlled CLARITY study. Mult Scler 15(Suppl 2): S248, Abstract P816.
77. Rituximab (Marketed and Rituxan) Information ( 2006) US Food and Drug Administration Center for Drug Evaluation and Research, US Department of Health and Human Services : Rockville, MD.
78. Romine, J.S., Sipe, J.C., Koziol, J.A., Zyroff, J. and Beutler, E. ( 1999) A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 111: 35-44.
79. Rudick, R.A., Stuart, W.H., Calabresi, P.A., Confavreux, C., Galetta, S.L., Radue, E.W. et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354: 911-923.
80. Saven, A., Burian, C., Koziol, J.A. and Piro, L.D. ( 1998) Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 92: 1918-1926.
81. Sipe, J.C., Romine, J.S., Koziol, J.A., McMillan, R., Zyroff, J. and Beutler, E. ( 1994) Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 344: 9-13.
82. Sipe, J.C. ( 2005) Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother 5: 721-727.
83. Smith, D. ( 2004) Preliminary analysis of a trial of pulse cyclophosphamide in IFN-beta-resistant active MS. J Neurol Sci 223: 73-79.
84. Smith, D.R., Weinstock-Guttman, B., Cohen, J.A., Wei, X., Gutmann, C., Bakshi, R. et al. (2005)
85. A randomized, blinded trial of combination therapy with cyclophosphamide in patients with active MS on interferon-beta. Mult Scler 11: 573-582.
86. Soelberg-Sorensen, P., Comi, G., Cook, S., Giovannoni, G., Rammohan, K., Rieckmann, P. et al. (2009) Effects of cladribine tablets on haematological profiles in patients with relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. Mult Scler 15(Suppl 2): S137, Abstract P472.
87. The Canadian Cooperative Multiple Sclerosis Study Group ( 1991) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337: 441-446.
88. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS / MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45: 1277-1285.
89. The International Multiple Sclerosis Genetics Consortium ( 2007) Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 357: 851-862.
90. van Boxel-Dezaire, A.H., Hoff, S.C., van Oosten, B.W., Verweij, C.L., Dräger, A.M., Adèr, H.J. et al. (1999) Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol 45: 695-703.
91. van de Wyngaert, F.A., Beguin, C., D'Hooghe, M.B., Dooms, G., Lissoir, F., Carton, H. et al. (2001) A double-blind clinical trial of mitoxantrone versus
92. methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurol Belg 101: 210-216.
93. Vartanian, T. ( 2003) An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis. Clin Ther 25: 105-118.
94. Vermersch, P., Comi, G., Cook, S., Giovannoni, G., Rammohan, K., Rieckmann, P. et al. (2009) Early onset of effect of treatment with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. Mult Scler 15(Suppl 2): S249, Abstract P817.
95. Vollmer, T., Panitch, H., Bar-Or, A., Dunn, J., Freedman, M.S., Gazda, S.K. et al. (2008) Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 14: 663-670.
96. Weiner, H.L. and Cohen, J.A. ( 2002) Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 8: 142-154.
97. Weiner, H.L., Mackin, G.A., Orav, E.J., Hafler, D.A., Dawson, D.M., La Pierre, Y. et al. (1993) Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 43: 910-918.
98. Yates, C.R., Krynetski, E.Y., Loennechen, T., Fessing, M.Y., Tai, H.L., Pui, C.H. et al. (1997) Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126: 608-614.
99. Yong, V.W., Chabot, S., Stuve, O. and Williams, G. ( 1998) Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 51: 682-689.
100. Zaffaroni, M., Rizzo, A., Baldini, S.M., Ghezzi, A. and Comi, G. ( 2008) Induction and add-on therapy with mitoxantrone and interferon beta in multiple sclerosis. Neurol Sci 29(Suppl 2): S230-S232.
101. Zipoli, V., Portaccio, E., Hakiki, B., Siracusa, G., Sorbi, S. and Amato, M.P. ( 2008) Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. J Neurol Sci 266: 25-30.